Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series Ltd: World’s leading Event Organizer

Back

Catherine H Schein

Catherine H Schein

University of Texas, USA

Title: The opposing faces of interferons

Biography

Catherine H. Schein developed the first industrial scale methods for producing recombinant interferons and related cytokines at Biogen SA. After transitioning to academia, her research group explored the differences in control of nuclease function mediated by type 1 and 2 IFNs and how this related to their different structures. Her current research at FfAME, an institute that specializes in polymerase design, novel nucleotides and viral diagnostics, uses viral sequence data to define pathogenic signatures that direct host and organ targeting, physicochemical property consensus sequences for multivalent vaccine design and identifying inhibitors of enterovirus replication

Abstract

Interferon (IFN) were among the first cytokines to be produced recombinant, and the first antiviral proteins to be marketed. Since initial cloning in the late 1970ies, many types of IFNs and a host of cellular proteins induced by IFNs have been identified that are important in attacking viruses directly (e.g., through nuclease induction) or indirectly, through affecting cellular proteins that are required for their replication. The most pathogenic viruses (for example, Ebola) have developed mechanisms to directly interfere with these pathways, which limits the use of IFN as a direct treatment. However, mediators capable of upregulating later steps in IFN-controlled pathways may provide novel therapies to evade these pathogen induced, intracellular blockades.

The antiviral activity of IFN is “hit and run” in nature. Typically, IFN concentrations rise rapidly in the first days after infection, and then drop to undetectable levels as antibody-based responses deal with circulating virus. There is mounting evidence that this decrease in IFN levels is essential. Chronically high levels of IFN, used in treating Hepatitis C infection or diseases without clear viral etiology, such as multiple sclerosis can cause side effects. High circulating concentrations of IFN and IFN-induced proteins are found in diseases characterized by systemic inflammation, including lupus erythematosus and rheumatoid arthritis. Thus a new group of anti-IFN therapeutics is now in testing, to control immune responses to these important biological response factors.